Showing results (61-70 of 105) with videos related to

Sort By:
Pageof 11
Bulletin of the World Health Organization|January 1, 1990
Metrifonate in healthy volunteers: interrelationship between pharmacokinetic properties, cholinesterase inhibition and side-effectsY Aden-Abdi, T Villén, O Ericsson, et al.
Pharmacogenetics|February 1, 1992
Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjectsT Andersson, C G Regårdh, Y C Lou, et al.
Lakartidningen|May 6, 1992
[Genotyping for drug metabolism capacity can give valuable clinical information]M Ingelman-Sundberg, I Johansson, M L Dahl, et al.
British Journal of Clinical Pharmacology|May 1, 1995
Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19M Chang, G Tybring, M L Dahl, et al.
Pharmacogenetics|December 1, 1996
CYP2C19 genotype and phenotype determined by omeprazole in a Korean populationH K Roh, M L Dahl, G Tybring, et al.
Clinical Pharmacokinetics|December 12, 2001
Quantitative pharmacogenetics of nortriptyline: a novel approachE E Kvist, A Al-Shurbaji, M L Dahl, et al.
British Journal of Clinical Pharmacology|April 1, 1996
Lack of effect of chloroquine on the debrisoquine (CYP2D6 and S-mephenytoin (CYP2C19) hydroxylation phenotypesC M Masimirembwa, L L Gustafsson, M L Dahl, et al.
Clinical Pharmacology and Therapeutics|August 1, 1996
Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activityJ A Carrillo, M L Dahl, J O Svensson, et al.
British Journal of Clinical Pharmacology|October 27, 2001
Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African populationM G Scordo, E Aklillu, U Yasar, et al.
British Journal of Clinical Pharmacology|September 1, 1990
Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypesM L Dahl-Puustinen, C Alm, L Bertilsson, et al.
Pageof 11